Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$374.94 USD

374.94
1,478,016

-5.92 (-1.55%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $374.71 -0.23 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Abbott (ABT) Receives FDA's Approval for the TriClip TEER System

by Zacks Equity Research

Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.

Zacks Equity Research

Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval

by Zacks Equity Research

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

Zacks Equity Research

Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space

by Zacks Equity Research

According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.

Zacks Equity Research

QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

by Zacks Equity Research

QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.

Zacks Equity Research

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Zacks Equity Research

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Align (ALGN) Debuts Invisalign Palatal Expander in New Markets

by Zacks Equity Research

Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.

Zacks Equity Research

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

by Zacks Equity Research

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Zacks Equity Research

Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising

by Zacks Equity Research

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.

Zacks Equity Research

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).

Zacks Equity Research

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

Zacks Equity Research

Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.

Zacks Equity Research

Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes

by Zacks Equity Research

Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.

Zacks Equity Research

Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution

by Zacks Equity Research

Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).

Zacks Equity Research

Here's Why Investors Should Buy ResMed (RMD) Stock Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.

Zacks Equity Research

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

by Zacks Equity Research

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Zacks Equity Research

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Zacks Equity Research

Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch

by Zacks Equity Research

The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.

Zacks Equity Research

Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval

by Zacks Equity Research

Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.

Zacks Equity Research

Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Stryker (SYK) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.

Zacks Equity Research

Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.

Zacks Equity Research

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.